Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The HBV drug entecavir - effects on HIV-1 replication and resistance.

The New England journal of medicine - 21 Jun 2007

McMahon Moira A, Jilek Benjamin L, Brennan Timothy P, Shen Lin, Zhou Yan, Wind-Rotolo Megan, Xing Sifei, Bhat Shridhar, Hale Braden, Hegarty Robert, Chong Curtis R, Liu Jun O, Siliciano Robert F, Thio Chloe L

Abstract excerpt

Entecavir, a drug approved by the Food and Drug Administration for the treatment of chronic hepatitis B virus (HBV) infection, is not believed to inhibit replication of human immunodeficiency virus type 1 (HIV-1) at clinically relevant doses. We observed that entecavir led to a consistent 1-log(10) decrease in HIV-1 RNA in three persons with HIV-1 and HBV coinfection, and we obtained supportive in vitro evidence...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD4 Lymphocyte Count
Share to Guanine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B

Share to HIV Reverse Transcriptase

Share to Lamivudine

Share to Reverse Transcriptase Inhibitors

Share to Reverse Transcription

Share to Zidovudine

Source

Open in PubMed Open full text

Identifiers

PMID: 17582071
DOI: 10.1056/NEJMoa067710
PMCID: PMC3069686

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The HBV drug entecavir - effects on HIV-1 replication and resistance.PMID 17582071Read ↗

The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients.Semantic proximity Read ↗

Entecavir therapy induces de novo HIV reverse-transcriptase M184V mutation in an antiretroviral therapy-naive patient.Semantic proximity Read ↗

[Entecavir].Semantic proximity Read ↗

Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy.Semantic proximity Read ↗

A low antiretroviral activity of the antihepatitis B drug entecavir may be enough to select for M184V in HIV-1.Semantic proximity Read ↗

Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response.Semantic proximity Read ↗

Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.Semantic proximity Read ↗

Entecavir can select for M184V of HIV-1: a case of an HIV/hepatitis B (HBV) naïve patient treated for chronic HBV.Semantic proximity Read ↗

Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine.Semantic proximity Read ↗

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.Semantic proximity Read ↗

Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight from entecavir resistance studies.Semantic proximity Read ↗

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.